Key Points
- Director John Ryan purchased 8,000 ASP Isotopes shares at an average price of $2.70, investing $21,600 and increasing his holdings by 1.23% to 660,222 shares.
- ASP Isotopes shares opened at $2.65, near their 52-week low of $2.51 and well below the 52-week high of $14.49. The company reported a quarterly loss of $0.28 per share, missing estimates, despite revenue of $5.12 million exceeding expectations.
- Analyst sentiment is mixed, with an average rating of “Hold” and a consensus price target of $13.00; institutional investors own 16.80% of the company.
ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) Director John Ryan purchased 8,000 shares of ASP Isotopes stock in a transaction on Monday, September 28th. The stock was bought at an average price of $2.70 per share, with a total value of $21,600.00. Following the transaction, the director owned 660,222 shares of the company's stock, valued at approximately $1,782,599.40. This represents a 1.23% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ASP Isotopes Stock Up 0.8%
NASDAQ ASPI opened at $2.65 on Thursday. The stock's 50-day moving average price is $3.75 and its 200-day moving average price is $4.91. The company has a quick ratio of 3.85, a current ratio of 3.87 and a debt-to-equity ratio of 0.76. ASP Isotopes Inc. has a 52 week low of $2.51 and a 52 week high of $14.49. The company has a market capitalization of $406.27 million, a P/E ratio of -2.01 and a beta of 3.59.
ASP Isotopes (NASDAQ:ASPI - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.11). The company had revenue of $5.12 million for the quarter, compared to analysts' expectations of $4.47 million. ASP Isotopes had a negative net margin of 427.98% and a negative return on equity of 64.99%.
Hedge Funds Weigh In On ASP Isotopes
A number of hedge funds have recently made changes to their positions in the business. The Manufacturers Life Insurance Company grew its position in shares of ASP Isotopes by 8.8% during the first quarter. The Manufacturers Life Insurance Company now owns 30,503 shares of the company's stock worth $135,000 after purchasing an additional 2,470 shares in the last quarter. ProShare Advisors LLC boosted its stake in ASP Isotopes by 29.0% in the 4th quarter. ProShare Advisors LLC now owns 16,904 shares of the company's stock worth $90,000 after purchasing an additional 3,803 shares during the period. Sanctuary Advisors LLC boosted its stake in ASP Isotopes by 22.2% in the 1st quarter. Sanctuary Advisors LLC now owns 24,615 shares of the company's stock worth $109,000 after purchasing an additional 4,465 shares during the period. Royal Bank of Canada grew its holdings in ASP Isotopes by 18.4% during the 1st quarter. Royal Bank of Canada now owns 37,954 shares of the company's stock valued at $167,000 after buying an additional 5,906 shares in the last quarter. Finally, Allegheny Financial Group grew its holdings in ASP Isotopes by 17.9% during the 1st quarter. Allegheny Financial Group now owns 40,649 shares of the company's stock valued at $180,000 after buying an additional 6,176 shares in the last quarter. Institutional investors own 16.80% of the company's stock.
Analysts Set New Price Targets
ASPI has been the topic of several analyst reports. Wall Street Zen raised shares of ASP Isotopes from a "strong sell" rating to a "sell" rating in a report on Saturday, August 22nd. Weiss Ratings restated a "sell (d-)" rating on shares of ASP Isotopes in a research report on Monday, September 21st. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, ASP Isotopes currently has an average rating of "Hold" and a consensus target price of $13.00.
Check Out Our Latest Analysis on ASPI
ASP Isotopes Company Profile
(
Get Free Report)
ASP Isotopes Inc (NASDAQ: ASPI) is a development-stage company focused on isotope enrichment and related technologies. The company is developing an isotope-separation platform known as the Aerodynamic Separation Process, which is intended to enrich selected chemical elements and isotopes for use in several specialized markets.
ASP Isotopes has identified applications in the nuclear energy, medical, semiconductor, and quantum-computing industries. Its development programs have included uranium enrichment as well as the production of specialty isotopes such as carbon-14, molybdenum-100, and silicon-28.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
